Anavex Life Sciences Corp.
- AVXL
- NASDAQ
- Biotechnology
- CNS Drug Development
- Clinical-Stage Biotech
$1.31
Today −11.49%Quote Oct 16, 2026, 08:00 PM UTC
−45.64%over the last month
Max drawdown −47.0%From 1-month high −47.0%3 months −45.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$121.4M
Quote Oct 16
Next earnings
Nov 24
Expected, not confirmed
Analyst target
$11.00
+739.7% from here
Floor
$1.20
8.1% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AVXLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
34
Founded
2004